TY - JOUR
T1 - Zika Virus Vaccine
T2 - Progress and Challenges
AU - Shan, Chao
AU - Xie, Xuping
AU - Shi, Pei Yong
N1 - Funding Information:
We thank all members of the P.-Y.S. lab and the collaborators for their hard work and support. The P.-Y.S. lab was supported by a University of Texas Medical Branch (UTMB) startup award, University of Texas STARs Award, UTMB Technology Commercialization Program Award, CDC grant for the Western Gulf Center of Excellence for Vector-Borne Diseases, Pan American Health Organization grant SCON2016-01353, the Kleberg Foundation Award, UTMB CTSA UL1TR-001439, and NIH grant AI127744.
Funding Information:
We thank all members of the P.-Y.S. lab and the collaborators for their hard work and support. The P.-Y.S. lab was supported by a University of Texas Medical Branch (UTMB) startup award, University of Texas STARs Award, UTMB Technology Commercialization Program Award, CDC grant for the Western Gulf Center of Excellence for Vector-Borne Diseases, Pan American Health Organization grant SCON2016-01353 , the Kleberg Foundation Award, UTMB CTSA UL1TR-001439 , and NIH grant AI127744 .
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/7/11
Y1 - 2018/7/11
N2 - The explosive emergence of Zika virus has inspired a global effort to develop vaccines. Zika virus, which is a flavivirus primarily transmitted by mosquitoes, can cause devastating congenital syndrome in fetuses of pregnant women, including microcephaly, craniofacial disproportion, spasticity, ocular abnormalities, and miscarriage. In adults, Zika infection has been linked to the autoimmune disorder Guillain-Barré syndrome. Thus, despite the current waning in newly reported Zika infections, an efficacious vaccine is urgently needed to help limit the emergence of another detrimental epidemic. Here we summarize the current status of the Zika vaccine pipeline and highlight the challenges for clinical efficacy trials. Shan et al. review the current status of the Zika virus vaccine pipeline, highlight the challenges for efficacy trial in humans, underline the knowledge gaps required for clinical development, and provide potential solutions to overcome the barriers toward licensure.
AB - The explosive emergence of Zika virus has inspired a global effort to develop vaccines. Zika virus, which is a flavivirus primarily transmitted by mosquitoes, can cause devastating congenital syndrome in fetuses of pregnant women, including microcephaly, craniofacial disproportion, spasticity, ocular abnormalities, and miscarriage. In adults, Zika infection has been linked to the autoimmune disorder Guillain-Barré syndrome. Thus, despite the current waning in newly reported Zika infections, an efficacious vaccine is urgently needed to help limit the emergence of another detrimental epidemic. Here we summarize the current status of the Zika vaccine pipeline and highlight the challenges for clinical efficacy trials. Shan et al. review the current status of the Zika virus vaccine pipeline, highlight the challenges for efficacy trial in humans, underline the knowledge gaps required for clinical development, and provide potential solutions to overcome the barriers toward licensure.
UR - http://www.scopus.com/inward/record.url?scp=85048570657&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048570657&partnerID=8YFLogxK
U2 - 10.1016/j.chom.2018.05.021
DO - 10.1016/j.chom.2018.05.021
M3 - Review article
C2 - 30008291
AN - SCOPUS:85048570657
VL - 24
SP - 12
EP - 17
JO - Cell Host and Microbe
JF - Cell Host and Microbe
SN - 1931-3128
IS - 1
ER -